Sanofi's con­tro­ver­sial dengue vac­cine wins FDA ap­proval, with a raft of caveats

Sanofi’s con­tro­ver­sial dengue vac­cine, which took two decades to de­vel­op, has made it across the FDA fin­ish line — but it wasn’t pret­ty. Less than a month af­ter a pan­el of ex­perts de­liv­ered mixed re­views for the shot, on Wednes­day, the US health reg­u­la­tor sanc­tioned the use of Deng­vax­ia as the first-ever prod­uct to pre­vent the mos­qui­to-borne dis­ease in cer­tain in­di­vid­u­als who have pre­vi­ous­ly con­tract­ed dengue and who live in ar­eas rife with the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER